糖尿病對於41歲以上非轉移性乳癌病患之化學治療毒性及病情影響: 以台灣人口為基礎的世代研究

以作者查詢圖書館館藏

、以作者查詢臺灣博碩士

、以作者查詢全國書目

、勘誤回報

、線上人數：15

、訪客IP：18.223.205.151

姓名

陳彥君(Yan-jun Chen) 查詢紙本館藏

畢業系所

系統生物與生物資訊研究所

論文名稱

糖尿病對於41歲以上非轉移性乳癌病患之化學治療毒性及病情影響: 以台灣人口為基礎的世代研究
(Impact of diabetes on chemotherapy toxicity and outcomes of non-metastatic breast cancer patients aged 41 or above: a population-based cohort study in Taiwan)

相關論文

★ miRCSC : miRNA表現量伴隨癌症改變狀態的文獻證明搜尋引擎	★ 利用上下文感知最大化邊界神經網路提取疾病與疾病的關聯
★ 應用嵌入式系統於呼吸肌肉群訓練儀之系統開發	★ 勃起障礙與缺血性心臟病的雙向研究: 以台灣全人口基礎的世代研究
★ 基質輔助雷射脫附飛行時間式串聯質譜儀微生物抗藥性資料視覺化工具	★ 使用穿戴式裝置分析心律變異及偵測心律不整之應用程式
★ 建立一個自動化分析系統用來分析任何兩種疾病之間的關聯性透過世代研究設計以及使用承保抽樣歸人檔	★ 青光眼病患併發糖尿病,使用Metformin及Sulfonylurea治療得到中風之風險:以台灣人口為基礎的觀察性研究
★ 利用組成識別和序列及空間特性構成之預測系統來針對蛋白質交互作用上的特殊區段點位進行分析及預測辨識	★ 新聞語意特徵擷取流程設計與股價變化關聯性分析
★ 藥物與疾病關聯性自動化分析平台設計與實作	★ 建立財務報告自動分析系統進行股價預測
★ 建立一個分析疾病與癌症關聯性的自動化系統	★ 基於慣性感測器虛擬鍵盤之設計與實作
★ 一個醫療照護監測系統之實作	★ 應用手機開發手握球握力及相關資料之量測

檔案

[Endnote RIS 格式]

[Bibtex 格式]

[相關文章]

[文章引用]

[完整記錄]

[館藏目錄]

[檢視]

[下載]

本電子論文使用權限為同意立即開放。
已達開放權限電子全文僅授權使用者為學術研究之目的，進行個人非營利性質之檢索、閱讀、列印。
請遵守中華民國著作權法之相關規定，切勿任意重製、散佈、改作、轉貼、播送，以免觸法。

摘要(中)

癌症是一種不正常細胞不受控制的生長和擴散。在過去幾年癌症一直是死亡原因的第一名，在2010年癌症的標準死亡率是131.6 (每十萬人為單位)。在台灣的女性癌症中乳癌是最常見的一種癌症。臨床資料顯示乳癌和糖尿病之間有複雜的關聯，而且有研究指出在乳癌的病人中患有糖尿病的病人有較高的死亡率。然而在針對乳癌病人化療毒性的住院率的研究，目前沒有以台灣人口為基礎的研究。根據以上這些理由，我們的研究會著重於以下幾點: 1. 在台灣乳癌病人中有得糖尿病的病人數。 2. 了解有糖尿病的乳癌患者其存活率的情形。 3.統計乳癌病患因為化療毒性而住院的情況。

摘要(英)

Cancer is a group of disease characterized by uncontrollable growth and spread of abnormal cells. In Taiwan, cancer is the first most common cause of death in the past few years. The standardized mortality rate for cancer was 131.6 deaths/100,000 people in 2010. The breast cancer is the most common form of cancer among Taiwanese woman. Preclinical and clinical data suggest complex associations between diabetes and a number of studies have indicated that diabetes is associated with higher mortality in patients with breast cancer. There are no population-based data on hospitalization rate for toxicity from breast cancer chemotherapy in Taiwan. According to above reason, our research will focus on following items: First, the number of breast cancer patients with diabetes. Second, the survival state of patients with diabetes. Third, the hospitalization state of patients received chemotherapy.

關鍵字(中)

★ 乳癌
★ 存活率
★ 化療毒性
★ 全民健康保險研究資料庫

關鍵字(英)

★ Chemotherapy Toxicity
★ National Health Insurance Research Database
★ NHIRD
★ breast cancer
★ Survival rate

論文目次

Chinese Abstract....................................................................................................................................I
English Abstract....................................................................................................................................II
Table of Contests.................................................................................................................................III
List of Figures …..………………………………......................................……………………………………..………………..IV
List of Tables…...................................…………………………………………………………………………………...………….V
Chapter 1 INTRODUCTION……………………..…………………………………………………………………………………1
1-1 Background…………………………………………………………………………………………………………………………..1
1-2 Motivation……………………………………………………………………………………………………………………………2
1-3 Research Goal……………………………………………………………………………………………………………………….2
Chapter 2 RELATED WORKS...............……………………………………………………………………………………....3
2-1 Survival Rates of Breast Cancer Patients with Diabetes........................................................3
2-2 Chemotherapy Toxicity..........................................................................................................4
Chapter 3 MATERIALS AND METHODS……………………………………………………….....……………….…….….6
3-1 Data Source………………………………………………………………………………………………………………………6
3-2 NHIRD Field Selection……………………………………………………………………………………………………….6
3-3 Study Population………………………………………………………………………………………………………………6
3-4 Data Extraction and Definitions…………………………………………………………………………………………9
3-5 Statistical Analyses………………………………………………………………………………………….………………10
Chapter 4 RESULTS…………………………………………………………………………………………………….……………11
4-1 Baseline Characteristics………………………………………………………………………………………………….11
4-2 Diabetes Status with Chemotherapy Use………………………………………………………………………..21
4-3 Chemotherapy Regimens and Toxic Effects………………………………………………………………..……31
Chapter 5 DISCUSSION…………………………………………………………………………………….………………….....34
REFFERENCES………………………………………………………………………………………………………………38
APPENDIXS…………………………………………………………………………………………………………………………41

參考文獻

1. Society, A.C., Cancer Facts & Figures 2010. 2010, Atlanta: American Cancer Society.
2. National Health Insurance Annual Causes Of Death Statistical Report 2010. 2010, Taiwan:Bureau of National Health Insurance: Taipei.
3. Chang, K.J., W.H. Kuo, and M.Y. Wang, The Epidemiology of Breast Cancer in Taiwan. JCOS, 2008. 24(2): p. 85-93.
4. Cheng, S.H., et al., Unique features of breast cancer in Taiwan. Breast Cancer Res Treat, 2000. 63(3): p. 213-23.
5. Lee, J.H., et al., Population-based breast cancer statistics in Korea during 1993-2002: incidence, mortality, and survival. J Korean Med Sci, 2007. 22 Suppl: p. S11-6.
6. Cancer incidence and incidence rates in Japan in 1994: estimates based on data from seven population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan. Jpn J Clin Oncol, 1999. 29(7): p. 361-4.
7. Minami, Y., et al., The increase of female breast cancer incidence in Japan: emergence of birth cohort effect. Int J Cancer, 2004. 108(6): p. 901-6.
8. Mellemkjaer, L., et al., Risk of second cancer among women with breast cancer. Int J Cancer, 2006. 118(9): p. 2285-92.
9. Lee, K.D., et al., Increased risk for second primary malignancies in women with breast cancer diagnosed at young age: a population-based study in Taiwan. Cancer Epidemiol Biomarkers Prev, 2008. 17(10): p. 2647-55.
10. Yancik, R., et al., Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA, 2001. 285(7): p. 885-92.
11. Czyzyk, A. and Z. Szczepanik, Diabetes mellitus and cancer. Eur J Intern Med, 2000. 11(5): p. 245-252.
12. La Vecchia, C., et al., A case-control study of diabetes mellitus and cancer risk. Br J Cancer, 1994. 70(5): p. 950-3.
13. Weiss, H.A., et al., Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol, 1999. 28(5): p. 816-23.
14. Hjalgrim, H., et al., Cancer and diabetes--a follow-up study of two population-based cohorts of diabetic patients. J Intern Med, 1997. 241(6): p. 471-5.
15. Coughlin, S.S., et al., Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol, 2004. 159(12): p. 1160-7.
16. Wideroff, L., et al., Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst, 1997. 89(18): p. 1360-5.
17. Baron, J.A., et al., Metabolic disorders and breast cancer risk (United States). Cancer Causes Control, 2001. 12(10): p. 875-80.
18. Weiderpass, E., et al., Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer, 1997. 71(3): p. 360-3.
19. Talamini, R., et al., Selected medical conditions and risk of breast cancer. Br J Cancer, 1997. 75(11): p. 1699-703.
20. Mink, P.J., et al., Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol, 2002. 156(4): p. 349-52.
21. Michels, K.B., et al., Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care, 2003. 26(6): p. 1752-8.
22. Wolf, I., et al., Diabetes mellitus and breast cancer. Lancet Oncol, 2005. 6(2): p. 103-11.
23. Srokowski, T.P., et al., Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J Clin Oncol, 2009. 27(13): p. 2170-6.
24. Tammemagi, C.M., et al., Comorbidity and survival disparities among black and white patients with breast cancer. JAMA, 2005. 294(14): p. 1765-72.
25. Barone, B.B., et al., Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA, 2008. 300(23): p. 2754-64.
26. Lipscombe, L.L., et al., The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat, 2008. 109(2): p. 389-95.
27. Zhou, X.H., et al., Diabetes, prediabetes and cancer mortality. Diabetologia, 2010. 53(9): p. 1867-76.
28. Tseng, C.H., C.K. Chong, and T.Y. Tai, Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia, 2009. 52(2): p. 240-6.
29. Du, X. and J.S. Goodwin, Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol, 2001. 19(5): p. 1455-61.
30. Du, X.L., C. Osborne, and J.S. Goodwin, Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol, 2002. 20(24): p. 4636-42.
31. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr, 2001(30): p. 5-15.
32. Shapiro, C.L. and A. Recht, Side effects of adjuvant treatment of breast cancer. N Engl J Med, 2001. 344(26): p. 1997-2008.
33. Chiu, Y.M. and C.H. Lai, Nationwide population-based epidemiologic study of systemic lupus erythematosus in Taiwan. Lupus, 2010. 19(10): p. 1250-5.
34. Chen, C.S., et al., Does high surgeon and hospital surgical volume raise the five-year survival rate for breast cancer? A population-based study. Breast Cancer Res Treat, 2008. 110(2): p. 349-56.
35. Hebert, P.L., et al., Identifying persons with diabetes using Medicare claims data. Am J Med Qual, 1999. 14(6): p. 270-7.
36. Chavez-MacGregor, M., et al., Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer. Cancer, 2011: p. n/a-n/a.
37. Charlson, M.E., et al., A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987. 40(5): p. 373-83.
38. Deyo, R.A., D.C. Cherkin, and M.A. Ciol, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol, 1992. 45(6): p. 613-9.
39. Guastamacchia, E., et al., Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord, 2003. 3(3): p. 205-9.
40. Fleming, S.T., et al., A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care, 1999. 37(6): p. 601-14.
41. Satariano, W.A. and D.R. Ragland, The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med, 1994. 120(2): p. 104-10.
42. Rutqvist, L.E., Validity of certified causes of death in breast carcinoma patients. Acta Radiol Oncol, 1985. 24(5): p. 385-90.
43. Meyerhardt, J.A., et al., Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol, 2003. 21(3): p. 433-40.

指導教授

洪炯宗(Jorng-tzong Horng)

審核日期

2011-7-26

推文